Indication
Major Depressive Disorder
The Major Depressive Disorder pipeline: 67 tracked drugs, 7 approved for this indication.
7 approved / phase 411 Phase 32 Phase 2/337 Phase 21 Phase 1/26 Phase 13 preclinical / unstaged
Compare the share prices of listed companies in Major Depressive Disorder →
Total attributable cost
$127.3B
$6,429/patient
Drug spend
Not yet sourced
All severities (2019 claims-based estimate) · US